ArticleScientific reports2025
Analyses of the mechanism and therapeutic targets of senescence related genes in ischemic stroke with multi-omics approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep Learning-Enabled Multi-Omics Integration: A New Frontier in Precise Drug Target Discovery.Biology · 2026Review
- Systems-level analysis uncovers eight hub genes and a resveratrol-based therapeutic strategy for ischemic stroke.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Ischemic stroke (IS) affects 11 million people annually, posing substantial clinical and economic burdens. Current therapies remain limited by time sensitivity and variable efficacy, necessitating novel biomarkers. We developed a multi-omics framework to investigate senescence-associated gene regulation in IS. After normalizing GSE22255 and GSE58294 datasets, we systematically identified aging-related differentially expressed genes (DEGs). Functional annotation via Gene Set Enrichment Analysis (GSEA) and machine learning-driven Weighted Gene Co-expression Network Analysis (WGCNA) identified core genetic signatures validated in the GSE16561 cohort. Key regulators underwent single-gene profiling, immune microenvironment evaluation, and transcriptional network analysis. Reverse transcription-quantitative PCR (RT-qPCR) confirmed bioinformatics findings. We identified 132 senescence-related DEGs, with PTGS2 emerging as a key biomarker. Pathway analyses revealed significant NF-κB, HIF-1, and TGF-β signaling pathway activation. CIBERSORT-based immune profiling showed altered lymphocyte/macrophage ratios in IS patients. Drug-gene interaction analysis identified nine therapeutic compounds, including etodolac targeting NFE2L2 and PTGS2. A strong positive correlation (r = 0.72, p < 0.001) between NFE2L2 and PTGS2 expression was observed. This study establishes senescence-related genes as promising biomarkers and therapeutic targets for IS, particularly through NFE2L2-PTGS2 interactions, providing a foundation for developing immunomodulatory and targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.